DELTICOM
7.4.2016 15:07:25 CEST | Business Wire | Press release
Springtime is tyre-changing time. However, some people who have been driving on old winter tyres might consider wearing them out completely by leaving them for all summer, thus saving themselves the cost of having the tyres changed as well as the possible cost of a new set of summer tyres. By doing so, they sacrifice their own safety and purchasing efficiency.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160407005795/en/
The properties of summer and winter tyres are designed to meet the specific requirements of weather conditions at different times of year. In this way, they ensure optimum efficiency and safety in the prevailing weather conditions. While it may be very tempting to drive straight through to autumn on winter tyres, in warm temperatures summer tyres are a better choice. The general rule of thumb is: from Easter to October. Once the average temperature is mostly above seven degrees Celsius, summer tyres show off all their advantages.
Even Germany’s largest automobile association, ADAC, warns against driving on winter tyres during summer. The reason: due to the soft tread compound used in winter tyres, they are not suited to warm temperatures and offer less grip. When the weather gets warmer, the tread quickly wears off and braking performance is significantly affected. ADAC tests on winter tyres have shown that in summer, stopping distances at approx. 60mph/h may be extended by up to 16 metres. If tyres are also heated further through heavy vehicle loads, winter tyre side walls can suffer damage, and parts of the tread can even come unstuck.
“We recommend changing to summer tyres now, because they are the only tyres that offer the right custom profile and special rubber compound for warmer weather and therefore ensure good grip and shorter breaking distances”, advises Thierry Delesalle from Mytyres.co.uk. “If you’re thinking of leaving your winter tyres on, you won’t do your wallet any favours: in warm weather, winter tyres can increase fuel consumption by up to 15%”, explains Delesalle.
So save now and hit the road properly equipped: just click on Mytyres.co.uk and enjoy a wide range of suitable summer tyres at great prices - quickly, easily and securely. Tyres can be delivered either to the customer’s preferred address, or to one of over 2,000 partner fitting stations across the UK. Many partner workshops also offer customers competitive prices for storing their winter tyres at the workshop until the following winter.
The most important hints on the changing of summer tyres can be also found in the following video: https://www.youtube.com/watch?v=OE5wWgUmi2k&nohtml5
About Mytyres.co.uk
There are over 100 tyre brands and more than 25,000 models of tyres to be found at Mytyres.co.uk - also including the latest best-rated tyres from official comparison tests. The product portfolio not only includes tyres for cars , motorbikes , lorries, commercial vehicles and buses , but also wheel-tyre sets , rims and car replacement parts and accessories . Particularly practical: new tyres can be delivered quickly and free of charge* to any address provided. When purchasing tyres, buyers can also choose from more than 2,000 professional car workshop partners across the UK and have the tyres sent to them directly for professional fitting. Many of our partner workshops offer also additional services, such as tyre storage.
*2 tyres and more
Buy tyres online:
www.mytyres.co.uk , www.reifendirekt.de , www.reifendirekt.at , www.reifendirekt.ch , www.123pneus.ch , www.autobandenmarkt.nl , www.123pneus.fr , www.gommadiretto.it , www.neumaticos-online.es and in many other Delticom online shops.
Tyre tests: www.tyretest.com
Information about the company: www.delti.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160407005795/en/
Contact:
insignis Agency for Kommunikation GmbH (GPRA)
Henning Jahns
Tel.:
+49-511-132214-14
Fax: +49-511-132214-99
delticom@insignis.de
or
Delticom
AG
Anne Lena Peters
Tel.: +49-511-93634-8909
Fax:
+49-511-93634-8301
anne.lena.peters@delti.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom